Pharmaceutical and Healthcare latest pipeline guide Male Hypogonadism Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Male Hypogonadism (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The Male Hypogonadism Pipeline report covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
Male hypogonadism is a condition in which the body doesn’t produce enough testosterone. Symptoms include fatigue, hot flashes, infertility, decrease in muscle mass and loss of bone mass (osteoporosis). Risk factors for hypogonadism include HIV/AIDS, Klinefelter syndrome, Kallmann syndrome, injury to testicles and untreated sleep apnea. Treatment includes hormone replacement.
Discount is available on Male Hypogonadism report at http://www.reportsnreports.com/contacts/discount.aspx?name=1132642 .
The Male Hypogonadism (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Male Hypogonadism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 5, 1, 4, 4, 2, 1 and 4 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.
Purchase This Single User License PDF Report of 100 pages at: http://www.reportsnreports.com/purchase.aspx?name=1132642 .
Male Hypogonadism (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Male Hypogonadism – Companies Involved in Therapeutics Development
Antares Pharma Inc, Clarus Therapeutics Inc , EndoCeutics Inc, Ferring International Center SA, Lipocine Inc, M et P Pharma AG, Medlab Clinical Ltd, Merck & Co Inc, Mereo Biopharma Group Plc, Repros Therapeutics Inc , TesoRx Pharma LLC, The Female Health Company, Viramal Ltd
List of Figures
Number of Products under Development for Male Hypogonadism, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products by Targets, H2 2017
Number of Products by Stage and Targets, H2 2017
Number of Products by Mechanism of Actions, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017
ReportsandReports.com is your single source for all market research needs. Our database includes 100,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.
2nd Floor, Metropole,
Bund Garden Road,
Pune – 411001,
Tel: + 1 888 391 5441